Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical has some of the best combined metrics of any stock in the market today, yet is constantly tagged as overvalued.

Intuitive Surgical Vs. Wall Street's Heavyweights: Highly Valued Or Overvalued?

Lemonade

Texas Instruments

Markets are up big again so far this year, but don't fear you've missed the boat.

Forget a Market Crash, Start Buying These 3 Stocks Now

Apple

Abbott Labs

Butterfly Network

Globus Medical

HealthCor Catalio Acquisition Corp

A look at a new SPAC in the healthcare business with great long-term potential.

The Next Nano-X, but With Less Risk?

Chipotle

Netflix

Chicken Soup for the Soul Entertainment

Origin Materials

With the trading day roughly halfway over, the broad markets were continuing their rally from Tuesday.

Box, Chipotle, Netflix and More Wednesday Afternoon Analyst Upgrades and Downgrades

Intuitive Surgical's (ISRG) second-quarter results reflect strong segmental performance.

Intuitive Surgical (ISRG) Q2 Earnings & Revenues Top Estimates

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q2 2021 Results - Earnings Call Transcript

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 24.05% and 13.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Surpasses Q2 Earnings and Revenue Estimates

Both these companies released earnings results after the market closed, but only one saw its stock rise after hours.

How Netflix, Intuitive Surgical Fared After Tuesday's Stock Market Rebound

Shares of Intuitive Surgical (NASDAQ:ISRG) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 253.15% over the past year to $3.92, which beat the estimate of $3.06.

Intuitive Surgical: Q2 Earnings Insights

Intuitive Surgical, a fast growing robotic surgical platform company, is scheduled to report its Q2 2021 results on Tuesday, July 20. We expect Intuitive Surgical to likely beat the revenue and earnings expectations, driven by continued rebound in total procedure volume.

Will Intuitive Surgical Stock Rise Post Q2 Results?

AT&T

Twitter

Halliburton

Snap

United Continental Hlds

Second-quarter earnings season ramps up this week with results from IBM, Netflix, Chipotle, United Airlines, Coca-Cola, Johnson & Johnson, Verizon, AT&T, Twitter, Snap, Intel, and many more.

Netflix, AT&T, Snap, Chipotle, Twitter, and Other Stocks to Watch This Week

CrowdStrike

Veeva Systems

Recurring revenue and network effects make these terrific stocks to buy on the dips.

3 Stocks to Buy in the Upcoming Market Crash

Alphabet

Pinterest

Market declines are commonplace, but also the perfect time to put capital to work.

Who's Ready for a Stock Market Crash? 3 Stocks to Buy Hand Over Fist When It Happens

In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $950.11, marking a -0.37% move from the previous day.

Intuitive Surgical, Inc. (ISRG) Stock Moves -0.37%: What You Should Know

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance at Instruments & Accessories segment.

What's in Store for Intuitive Surgical's (ISRG) Q2 Earnings?

Curaleaf Holdings, Inc.

Danaher

GlaxoSmithKline

IQVIA Hlds

Jazz Pharmaceuticals

LHC Group

Moderna

Invesco S&P 500 Equal Weight Health Care ETF

UnitedHealth Group

Vertex Pharmaceuticals

The 2020s could be the decade of healthcare stocks. Here are 10 companies and one ETF to watch not just for the remainder of this year, but well beyond.

11 Best Healthcare Stocks for the Rest of 2021

Amazon

Brookfield Renewable Partners

These stocks should be surefire winners over the long term.

3 Unstoppable Stocks to Buy Instead of AMC

The stock price of Intuitive Surgical has seen a 15% rise over the last twenty-one trading days, while it is up a solid 64% over the last year. ISRG stock has benefited from a rebound in volume of procedures and strong Q1 results.

Will Intuitive Surgical Stock Continue Its Rally After A 15% Rise In A Month?

Restaurant Brands

Winnebago

With concerns about the pandemic subsiding, these companies have been posting better results of late.

3 Reopening Stocks to Buy Now

A Stock Market Crash Is Unavoidable: 3 No-Brainer Stocks to Buy When It Happens

Microsoft

NVIDIA's recent announcement could open the floodgates for more companies to step forward.

These 3 Winners Look Ready for a Stock Split

We believe that the stock price of Intuitive Surgical (NASDAQ: ISRG) appears fully valued at the current levels of around $900, and it is vulnerable to downside risk. ISRG stock is up 2.5x from the levels of around $367 it was at on March 23, 2020, when broader markets made a bottom.

Intuitive Surgical Stock Is Richly Valued At $900 Levels

Etsy

Innovative Industrial Properties

No, they won't deliver the returns going forward that AMC has so far this year. But neither will AMC.

News for Intuitive Surgical Stock (ISRG)